Hong Kong – Employment agent of foreign domestic helpers jailed for conspiracy to defraud

Employment agent of foreign domestic helpers jailed for conspiracy to defraud


     An employment agent of foreign domestic helpers (the employment agent) was convicted of two counts of conspiracy to defraud and was sentenced to 15 months’ imprisonment today (September 24) at the Shatin Magistrates’ Courts. Twenty-three foreign domestic helpers involved in the case had been convicted earlier for the offence of making false representation to an immigration officer, and were sentenced to up to eight months’ imprisonment.

     The employment agent is a 56-year-old Hong Kong permanent resident. Since April 2018, the Immigration Department (ImmD) has processed several foreign domestic helper (FDH) visa applications through the same employment agent. After in-depth and thorough comparisons, the ImmD detected several suspicious employers’ residential and financial proofs and triggered the investigation of the employment agent. In July 2018, ImmD investigators mounted a series of operations. Twenty-four persons, comprising the employment agent and 23 foreigners who had applied for FDH visas using false contracts, were apprehended. During the enforcement action, two computers and four mobile phones were seized, and respective false employers’ proofs were discovered after conducting forensic examinations.

     An investigation of the other suspects is continuing.
     “It is an offence to make false representation to an immigration officer. Offenders are liable to prosecution and to a maximum fine of $150,000 and imprisonment for 14 years. In addition, anyone who commits the offence of conspiracy to defraud is liable to prosecution and, upon conviction, the maximum penalty is imprisonment for 14 years. Furthermore, it is an offence to make, possess or use false instruments. Upon conviction, offenders are liable to a maximum penalty of 14 years’ imprisonment,” an ImmD spokesman said.

BAS Agent Services Introduced by Whiz Consulting

 Business Activity Statement (BAS) is a vital aspect of running a business in Australia. Not every business best outsourced accounting and bookkeeping services providers. It provides its services to businesses irrespective of its operation size or the industry it belongs to. The sources from Whiz Consulting stated the new service had been long due. While they have been assisting businesses with BAS lodging and report from before for almost all their clients, the addition of BAS agent services will open up the door for businesses who do not have their own in-house bookkeeper or don’t want to hire another BAS agent individual.

It is important to note that not every individual can file and report BAS. Only a certified BAS agent can conduct BAS filing and reporting. Or else, you must have an in-house full-time bookkeeper who can take the responsibility of BAS agent. So what is the reason behind this launch? A senior executive at Whiz Consulting stated, “GST, BAS, and tax return preparations come with complex provisions and should be handled by experts. BAS lodging time can differ from one business to another as it depends on its annual turnover. BAS is lodged to ATO with summaries of the business’s tax obligations, including GST, PAYG instalments, PAYG withholding FBT, WET, and a few other taxes applicable to a specific business. We have seen businesses struggling with their BAS, and we wanted to provide a service which will encompass the overall BAS lodging and reporting process.”

Whiz Consulting has put much thought when launching BAS agent services. BAS agent services are necessary for businesses who are obligated to lodge BAS but do not have full-time bookkeeping hired for their business which can perform the duties of a BAS agent. Imagine the plights of the small businesses outsourcing their bookkeeping services and do not have their in-house bookkeeping personnel. An outsourced bookkeeper helps maintain a business’s accounting records, but they can fullfill the role of a BAS agent. Firstly, the role of a BAS agent is more diverse, and secondly, BAS agents are registered with the Tax Practitioners Board. Therefore Whiz Consulting’s BAS agent services will eliminate the need for you to approach two separate service providers. It can help you with your bookkeeping needs and provide BAS agent services, helping you streamline your business process and reduce processing time.

Whiz Consulting’s BAS agent services will include a wide range of services like applying to the registrar for ABN, advisory services to clients for their obligation under BAS provision, payroll processing, STP compliance, and super guarantee contribution. It will enable businesses to report and pay tax liabilities accurately on time.

About Whiz Consulting

Whiz Consulting is an outsourced bookkeeping and accounting services provider in Australia. Their team of skilled CPAs, bookkeepers and BAS agents assists businesses in seamless bookkeeping and accounting processes for firms based in Sydney, Brisbane, Adelaide, Queensland, and other parts of Australia. Along with bookkeeping & accounting, it also provides financial services like payroll processing, taxation, business advisory services, and industry-specific accounting.

Whiz Consulting Private Limited

David Brown





  • Accounting & Taxes

Real Estate Agent Judy Sin Closes 9 Sales While Navigating the “New World” of Real Estate

 Judy Sin, an experienced Compass real estate agent in Lamorinda, California, announced today a slew of new sales due to her transition into “new world” real estate brought on by the pandemic. Within the last two months, Sin has closed nine deals for over $10 million, with four of them closing for more than $1 million.

Sin is a real estate agent bred from the “new talent pool,” tasked with navigating the post-COVID world through flexibility, entrepreneurship, and the ability to be innovative. During the pandemic, Sin quickly adopted a new virtual workflow – conducting zoom consultations and facetime showings; prioritized social media marketing, reaching more than 70,000 people a month on Instagram; completing electronic transaction management; and allowing clients to sign documents anywhere nationwide.

“In the post-COVID world, real estate agents have been tasked with the goal of adjusting to a new model of being an agent – and I have been lucky to earn the trust of many through the use of technology,” Sin said. “This means conducting virtual meetings and walkthroughs, reducing face-to-face contact while also providing world-class customer service and making all my clients feel safe and comfortable.”

With all of these changes being thrust on the world of real estate, Sin has continued to adapt and find the best methods to embrace change.

“Today, agents need the ability to lead and market in a virtual world, and I am extremely happy to have helped sellers and buyers navigate a new world of real estate to ensure everyone is receiving the best possible deal,” Sin said. “Going forward, I will continue to adapt to the changes thrown our way by the pandemic to continue serving the community.”

Judy Sin and her family moved to Moraga before the pandemic and immediately welcomed 10 chickens to their family. Her curation of living, buying, and selling in Lamorinda, California on Instagram is liked and followed by thousands around the world.

Judy Sin | Selling Lamorinda

Judy Sin





  • Real Estate

Anticancer Agent “Remitoro Intravenous Drip Infusion 300 microgram” (Denileukin Diftitox (Genetical Recombination)) Launched in Japan

Eisai Co., Ltd. announced today that it has launched the anticancer agent “Remitoro® for Intravenous Drip Infusion 300μg” (Denileukin Diftitox (Genetical Recombination)) with the indications of relapsed or refractory Peripheral T-cell Lymphoma (PTCL) and relapsed or refractory Cutaneous T-cell Lymphoma (CTCL), in Japan. Eisai obtained the manufacturing and marketing approval of Remitoro on March 23, 2021. Remitoro was included to Japan’s National Health Insurance Drug Price List on May 19, 2021.

The agent is a fusion protein consisting of interleukin-2 (IL-2) and partial sequence of diphtheria toxin, and specifically binds to the IL-2 receptor on the surface of tumoral lymphocytes. The antitumor efficacy of denileukin diftitox is believed to depend on the intracellular delivery of diphtheria toxin fragment which inhibits protein synthesis and induce cell death.

The approval of Remitoro in Japan is based primarily on data from Study 205, which is a multicenter, open-label, single-arm Phase II clinical study, conducted in Japan to evaluate the efficacy and safety of the agent in patients with relapsed or refractory PTCL or CTCL.

Study 205 achieved the primary endpoint target and exceeded a prespecified tumor response threshold with statistical significance: the objective response rate (ORR) of PTCL and CTCL patients in total (n=36) was 36.1% (95% confidence interval (CI): 20.8-53.8). The ORRs of each subtype were 41.2% (95%CI: 18.4-67.1) for PTCL (n=17) and 31.6% (95% CI: 12.6-56.6) for CTCL (n=19).

The five most frequent treatment-emergent adverse events observed in this study were aspartate aminotransferase increased (AST) (89.2%), alanine aminotransferase increased (ALT) (86.5%), hypoalbuminaemia (70.3%), lymphopenia (70.3%), and pyrexia (51.4%).

Eisai will conduct a post-marketing special use results survey (all-case surveillance) in all patients who are administered the agent until a pre-determined number of patients has been reached in accordance with an approval condition imposed by the Ministry of Health, Labour and Welfare (MHLW).

According to a survey by the MHLW, it is estimated that, in Japan, the number of patients with PTCL is less than 6,000 and the number of patients with CTCL is less than 4000. These diseases may have a poor prognosis or be difficult to treat. Therefore, these are still diseases with extremely high-unmet medical need.

Remitoro was evaluated by the MHLW as a drug with high medical need at the “Study Group for Unapproved Drugs/Off-Label Drugs for High Medical Need”. Eisai retains exclusive development and marketing rights for the agent in Japan and Asia.

Eisai will deliver Remitoro as a new treatment option for relapsed or refractory PTCL and CTCL in Japan, and will appropriately conduct a post-marketing special use results survey (all-case surveillance) in accordance with an approval condition imposed by the MHLW and promote the proper use of this drug.

Eisai is committed to exploring the potential clinical benefits of Remitoro for cancer treatment, as it seeks to contribute to addressing the diverse needs of, and increasing the benefits provided to, patients with cancer, their families and healthcare professionals.

Topic: Press release summary